Sticks’n’Sushi, the Copenhagen-based restaurant and takeaway group operating 27 sites across the UK, Denmark and Germany, has been acquired by McWin Capital Partners, a London-based private equity firm with Gail’s, Vapiano and L’Osteria on its portfolio.

American businessman John Angelos has agreed to the sale of the Baltimore Orioles to a group led by David Rubenstein, Co-Founder and Co-Chairman of private equity firm The Carlyle Group, as part of a transaction valuing the baseball team at $1.7bn.

Walter Global Asset Management, the private equity unit of Canadian investment group Walter Financial, is acquiring a minority stake in Madryn Asset Management, a US manager that focuses on investments in healthcare innovation.

Growth equity investment firm Summit Partners has made a majority investment in CollisionRight, a US consolidator of automotive collision repair shops, with the new funding set to be used to support the company’s growth plan.

Arlington Capital Partners, a private investment firm specialising in government regulated industries, has made a majority investment in Afton Scientific, a US contract, development and manufacturing organisation dedicated to sterile manufacturing of injectable pharmaceuticals.

An affiliate of HIG Capital, a global alternative asset investment firm with $60bn of capital under management, has completed the take-private acquisition of DX Group, a British mail, courier and logistics company, for an aggregate consideration of £307m.

Union Square Advisors, a technology-focused investment bank, is expecting to see an increase in technology sector deal-making in 2024, with recent positive momentum continuing over the course of the year.

Trilantic Europe, a European private equity firm with a dedicated energy transition strategy, has acquired a 60% stake in AEROCOMPACT Group, a supplier of solar mounting solutions specialising in the development, production and distribution of substructures for mounting photovoltaic modules.

UK-based private equity firm Exponent is to acquire Galway-based generic drugmaker Channelle Pharma, in a deal said to be worth about €300m, after beating off competition from other PE firms, according to a report by the Irish Times.